ASH 2023 Highlights Podcast

In this episode, [14:41] Medicom’s correspondent covers 6 presentations from the annual meeting of the American Society of Hematology (ASH 2023), held in San Diego, CA, USA, from 9–12 December 2023.
The topics discussed are:

1. Novel standard of care in newly diagnosed MM
   Daratumumab added to bortezomib, lenalidomide, and dexamethasone (VRd) outperformed VRd alone in participants with previously untreated multiple myeloma (MM) who were eligible for autologous stem cell transplantation (ASCT). Improvements were seen in progression-free survival (PFS) rates, complete response (CR) rates, and minimal residual disease (MRD)-negativity rates. According to the authors, a new standard of care has arrived for this patient population.
2. AUGMENT-101: Excellent results for revumenib in R/R KMT2Ar leukaemia
   Revumenib appeared to be safe and efficacious in patients with relapsed or refractory (R/R) KMT2A gene rearranged (KMT2Ar) acute leukaemia, results of the phase 2 AUGMENT-101 trial showed.
3. Axatilimab may represent a new therapeutic strategy in chronic GvHD
   Axatilimab showed promising efficacy outcomes and a favourable safety profile in participants with chronic graft-versus-host disease (GvHD). Swift and durable responses were observed across subgroups. Therefore, axatilimab may represent a novel therapeutic strategy in patients with chronic GvHD.
4. Pomalidomide may become the first approved therapy for hereditary haemorrhagic telangiectasia
   In the first adequately powered randomised clinical trial on hereditary haemorrhagic telangiectasia (HHT), pomalidomide reduced epistaxis, improved quality of life (QOL), and increased haemoglobin and haematocrit levels, as compared to placebo.
5. TRANSFORM-1: High spleen volume reduction rates for navitoclax plus ruxolitinib in MF
   The combination of navitoclax plus ruxolitinib yielded improved efficacy outcomes as compared to ruxolitinib alone in patients with newly diagnosed myelofibrosis (MF), the first results of the phase 3 TRANSFORM-1 trial showed. Further analyses are ongoing to evaluate other outcomes such as overall survival and responses in subgroups of participants.
6. IsKia: Novel treatment regimen for MM delivers high MRD-negativity rates
   Isatuximab plus carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) as pre-transplant induction and post-transplant consolidation therapy increased MRD-negativity rates compared to KRd alone in participants with previously untreated multiple myeloma (MM).

Enjoy listening!

Copyright ©2024 Medicom Medical Publishers



Posted on 4 January 202427 June 2024